the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email .

By Kindler, Hedy
Interventional only

Phase III
Study No PI Title
IRB16-1055 Kindler, Hedy A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma Details
IRB14-0873 Kindler, Hedy A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy. Details
Phase II
Study No PI Title
IRB17-0004 Kindler, Hedy A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 with Pembrolizumab in Adults with Previously-Treated Malignant Pleural Mesothelioma Details
IRB16-1700 Kindler, Hedy Open Label, Phase II Study of Anti - Programmed Death – Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination with Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma PrE0505 Details
IRB16-1318 Kindler, Hedy A021501: Preoperative Extended Chemotherapy Vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas Details
IRB14-1381 Kindler, Hedy A Phase II study of the Anti-PD-1 Antibody Pembrolizumab in Patients with Malignant Mesothelioma Details
Phase I
Study No PI Title
IRB16-0417 Kindler, Hedy A Phase 1a/1b Study of CXCR4 Peptide Antagonist (LY2510924) Administered in Combination with the Anti-PD-L1 Antibody, Durvalumab (MEDI4736), in Advanced Refractory Solid Tumors Details
IRB16-0712 Kindler, Hedy An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination with Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects with Mesothelin-Expressing Predominantly Epithelial Mesothelioma or Nonsquamous Non-small-cell Lung Cancer Details
Study No PI Title
IRB15-1149 Kindler, Hedy A pilot window-of-opportunity study of the anti-PD-1 antibody pembrolizumab in patients with resectable malignant pleural mesothelioma Details
IRB13-1268 Kindler, Hedy Long-Term Follow-Up of Subjects who Have Participated in Aduro-Sponsored Protocols
11-0755 Kindler, Hedy The International Association for the Study of Lung Cancer IASLC Prospective Malignant Pleural Mesothelioma Staging Project

Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .